Folate DeficiencyDFS-IoFA-1NCT05792241
Acceptability and Nutritional Impact of Double-fortified Salt Containing Iodine and Folic Acid - Phase 1
An observational study of Folate Deficiency and Iodine Deficiency, run by University of California, Davis at 1 site in Ethiopia.
Trial summary
The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status and thereby reduce the risk of neural tube defects (NTDs), which are highly prevalent in Ethiopia. The project will be conducted in two phases. Read more about this study
- Who is it for?
- Ages 18 to 49 years, women only
- Conditions the study is for
- Folate Deficiency, Iodine Deficiency, Anemia, Macrocytic
- How many people
- 100 participants
- Where
- 1 siteEthiopia
- Study dates
- 26 Jun 2023to 1 May 2024
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 49 years
- Women only
- Adult
Study population: The study will be conducted in the central highlands of Oromia region in Ethiopia, approximately 2 hours from the capital Addis Ababa.
Who may be able to join
- Non-pregnant women 18-49 years of age
- Agree to use salt provided by the study team for the household salt disappearance study
- Provide written, informed consent.
Who cannot join
- Currently pregnant
- Presence of acute or chronic disease (such as diarrhea, febrile illness, or underlying metabolic disorder) that might affect the participant's dietary intake or folate status
- Currently using medicines (like anticonvulsants and cancer treatments) that affect folate metabolism
- Medically prescribed restriction of salt intake
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Evaluation of the Acceptability and Nutritional Impact of Double-fortified Salt Containing Folic Acid and Iodine Among Ethiopian Women of Reproductive Age - Assessment of Women's Nutritional Status and Salt Intakes in the Study Communities
The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status and thereby reduce the risk of neural tube defects (NTDs), which are highly prevalent in Ethiopia. The project will be conducted in two phases. The purpose of Phase 1, described herein, is to complete formative research in preparation for a community-based, randomized trial, which will be carried out in Phase 2. The objectives of Phase 1 are to: 1) assess the hematological condition and nutritional status with respect to folate, iodine, and other micronutrients among non-pregnant women of reproductive age (WRA) in the study communities, and 2) measure discretionary salt and dietary folate intakes of the women and their households.
Read the detailed description
Potentially eligible women of reproductive age (WRA) will be identified from existing community census records and will be listed sequentially. A random number generator will be used to select individual women from this list for possible participation in the Phase 1 studies. In cases where two or more WRA are selected from the same household (HH), one will be randomly selected for possible participation in the study and the other(s) will be replaced by a WRA from another HH, using the same random selection procedure. A member of the study team will then visit the homes of women who are selected for possible participation in Phase 1 to describe the study to them, assess their eligibility, and request their consent to participate. In particular, the data collector will present an initial disclosure statement concerning the screening interview and will then obtain descriptive information from verbally consenting women on their age, general health status, address, cell phone number (if available), and potential willingness to participate in the subsequent research studies. The data collector will review the women's health history and determine their eligibility for the Phase 1 study.
For women who found to be eligible to participate in the Phase 1 study, the field worker will describe the purpose of the study, the study procedures and related risks and benefits, the confidentiality of results, and the fact that participation is voluntary. After providing an opportunity for women to consult with family members and ask any questions to the research team, the field worker (in the presence of a neutral witness) will request written consent from the women to participate in the study. Additional questions will be asked of consenting women regarding their marital status, ethnicity, religion, educational level, and employment; and their housing characteristics (housing construction, water source, sanitary facilities, access to electricity and cell phone service); and selected HH assets.
All eligible, consenting women will be requested to report to the Chefe Donsa Health Center or one of the local health posts within the next one or two days following the initial screening interview for fasting blood collection, anthropometric assessment, additional interviews, and scheduling of subsequent home visits by the study team for full-day dietary observations to measure discretionary salt intake and folate intake and to initiate 24-hour urine collections to measure sodium and iodine excretion. The fasting blood specimens will be collected for a complete blood count and measurement of red blood cell (RBC) folate and serum folate, unmetabolized folic acid, vitamin B12, holo-transcobalamin, methyl malonic acid, other B vitamins, genetic polymorphisms that affect folate metabolism, thyroglobulin, glucose, insulin, retinol binding protein (RBP), ferritin, soluble transferrin receptor, C-reactive protein, and alpha-1 acid glycoprotein and to complete a malaria rapid diagnostic test (RDT). Serum retinol will be measured in a subset of 40 women to establish the relationship between serum retinol and RBP in the study population. Blood specimens may also be collected from a subset of 20 women for possible metabolomics assays and natural killer cell (immune function) assays. Women with a positive RDT and those subsequently found to have anemia (Hb<13.2 g/dL, to adjust for altitude) will be referred to the local health facility for treatment. Additional interviews will be completed to assess the women's birth history, contraceptive use, and household food insecurity.
All women will participate in dietary assessments and 24-hour urine collections on one day within four weeks of enrollment, and a randomly selected sub-set of 40 women will complete these studies on a second day one-to-two weeks later. The purpose of the second set of studies is to allow for calculation of intra-individual variation in intakes and urinary sodium and iodine excretion, which is necessary to estimate the distribution of usual discretionary salt and folate intake and urinary sodium and iodine excretion of the study population. The dietary studies will involve a dietitian who will remain in the participant's home throughout the day to weigh all foods included in mixed dishes and to weigh the amounts served and consumed. Portions of each food will be collected to analyze these in the laboratory for sodium and selected nutrient contents. The investigators The investigators will also carry out HH salt disappearance studies over a period of one week using iodized refined salt provided by the project to determine the rate of salt utilization in relation to HH size. This information will be used to estimate the quantities of salt that we will need to deliver during Phase 2.
- Keywords
- Ethiopia, Salt fortification
- Medical subject headings
- Folic Acid Deficiency, Anemia, Macrocytic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Women of reproductive age | Randomly selected women of reproductive age in study communities. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Folate status
Red blood cell (RBC) folate concentration using a microbiological assay
Measured: one week
Iodine status
24-hour urinary iodine excretion using the Sandell-Kolthoff color reaction
Measured: four weeks
Discretionary salt intake
In-home weighed record of dietary intake
Measured: four weeks
Household salt utilization
One-week difference in weight of salt provided by study team
Measured: six weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted31 Mar 2023
- Study start26 Jun 2023
- Primary completion15 Aug 2023
- Study completion1 May 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Folate DeficiencyStudies of the same condition, open and under way.
- More trials run by University of California, DavisThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 100 participants (actual)
Sponsor and investigators
- Lead sponsor
- University of California, Davis
- Sponsor type
- University, hospital or other
- Collaborators
- Ethiopian Public Health Institute, University of California, San Francisco, Nutrition International
- Responsible party
- Sponsor
- Investigators
- Kenneth H Brown, MD, Principal investigator, University of California, Davis
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05792241
- Sponsor's protocol ID
- 1834465
- Acronym
- DFS-IoFA-1
- Status last verified
- Mar 2025
- First submitted
- 3 Mar 2023
- Last updated
- 13 Mar 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Two years after completion of the data collection, the individual participant data (IPD) data sets will become publicly available to other investigators who have specific research questions that can be addressed by the data and that are not already under analysis by the core research team. Researchers who desire to have access to the clinical specimens will be requested to apply for the specimens and to describe the research question(s) they plan to address.
Publications
Agbemafle I, Woldeyohannes M, Tessema M, Fereja M, Arnold CD, Banjaw BT, Hussen A, Kebebe T, Goh YE, Arabi M, Martinez H, McDonald CM, Brown KH. Assessment of Women's Discretionary Salt Intake and Household Salt Utilization in Preparation for a Salt Fortification Trial in Oromia Region, Ethiopia. Matern Child Nutr. 2025 Apr;21(2):e13768. doi: 10.1111/mcn.13768. Epub 2024 Dec 13.
PubMed 39673143
Study at a glance
From the registry record, last updated by the sponsor on 13 Mar 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Evaluation of the Acceptability and Nutritional Impact of Double-fortified Salt Containing Folic Acid and Iodine Among Ethiopian Women of Reproductive Age - Assessment of Women's Nutritional Status and Salt Intakes in the Study Communities
- ClinicalTrials.gov ID
- NCT05792241
- Acronym / sponsor ID
- DFS-IoFA-1 / 1834465
- Keywords
- Ethiopia, Salt fortification
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 100 participants (actual)
- Lead sponsor
- University of California, DavisUniversity, hospital or other
- Collaborators
- Ethiopian Public Health Institute, University of California, San Francisco, Nutrition International
- Study start
- 26 Jun 2023 (actual)
- Primary completion
- 15 Aug 2023 (actual)
- Study completion
- 1 May 2024 (actual)
- First posted
- 31 Mar 2023 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The overarching objective of this two-phase project is to assess the effects of fortifying iodized salt with folic acid on improving women's folate status and thereby reduce the risk of neural tube defects (NTDs), which are highly prevalent in Ethiopia. The project will be conducted in two phases. The purpose of Phase 1, described herein, is to complete formative research in preparation for a community-based, randomized trial, which will be carried out in Phase 2. The objectives of Phase 1 are to: 1) assess the hematological condition and nutritional status with respect to folate, iodine, and other micronutrients among non-pregnant women of reproductive age (WRA) in the study communities, and 2) measure discretionary salt and dietary folate intakes of the women and their households.
Detailed description
Potentially eligible women of reproductive age (WRA) will be identified from existing community census records and will be listed sequentially. A random number generator will be used to select individual women from this list for possible participation in the Phase 1 studies. In cases where two or more WRA are selected from the same household (HH), one will be randomly selected for possible participation in the study and the other(s) will be replaced by a WRA from another HH, using the same random selection procedure. A member of the study team will then visit the homes of women who are selected for possible participation in Phase 1 to describe the study to them, assess their eligibility, and request their consent to participate. In particular, the data collector will present an initial disclosure statement concerning the screening interview and will then obtain descriptive information from verbally consenting women on their age, general health status, address, cell phone number (if available), and potential willingness to participate in the subsequent research studies. The data collector will review the women's health history and determine their eligibility for the Phase 1 study.
For women who found to be eligible to participate in the Phase 1 study, the field worker will describe the purpose of the study, the study procedures and related risks and benefits, the confidentiality of results, and the fact that participation is voluntary. After providing an opportunity for women to consult with family members and ask any questions to the research team, the field worker (in the presence of a neutral witness) will request written consent from the women to participate in the study. Additional questions will be asked of consenting women regarding their marital status, ethnicity, religion, educational level, and employment; and their housing characteristics (housing construction, water source, sanitary facilities, access to electricity and cell phone service); and selected HH assets.
All eligible, consenting women will be requested to report to the Chefe Donsa Health Center or one of the local health posts within the next one or two days following the initial screening interview for fasting blood collection, anthropometric assessment, additional interviews, and scheduling of subsequent home visits by the study team for full-day dietary observations to measure discretionary salt intake and folate intake and to initiate 24-hour urine collections to measure sodium and iodine excretion. The fasting blood specimens will be collected for a complete blood count and measurement of red blood cell (RBC) folate and serum folate, unmetabolized folic acid, vitamin B12, holo-transcobalamin, methyl malonic acid, other B vitamins, genetic polymorphisms that affect folate metabolism, thyroglobulin, glucose, insulin, retinol binding protein (RBP), ferritin, soluble transferrin receptor, C-reactive protein, and alpha-1 acid glycoprotein and to complete a malaria rapid diagnostic test (RDT). Serum retinol will be measured in a subset of 40 women to establish the relationship between serum retinol and RBP in the study population. Blood specimens may also be collected from a subset of 20 women for possible metabolomics assays and natural killer cell (immune function) assays. Women with a positive RDT and those subsequently found to have anemia (Hb<13.2 g/dL, to adjust for altitude) will be referred to the local health facility for treatment. Additional interviews will be completed to assess the women's birth history, contraceptive use, and household food insecurity.
All women will participate in dietary assessments and 24-hour urine collections on one day within four weeks of enrollment, and a randomly selected sub-set of 40 women will complete these studies on a second day one-to-two weeks later. The purpose of the second set of studies is to allow for calculation of intra-individual variation in intakes and urinary sodium and iodine excretion, which is necessary to estimate the distribution of usual discretionary salt and folate intake and urinary sodium and iodine excretion of the study population. The dietary studies will involve a dietitian who will remain in the participant's home throughout the day to weigh all foods included in mixed dishes and to weigh the amounts served and consumed. Portions of each food will be collected to analyze these in the laboratory for sodium and selected nutrient contents. The investigators The investigators will also carry out HH salt disappearance studies over a period of one week using iodized refined salt provided by the project to determine the rate of salt utilization in relation to HH size. This information will be used to estimate the quantities of salt that we will need to deliver during Phase 2.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Women of reproductive age | – | –Randomly selected women of reproductive age in study communities. |
Who may qualify
- Ages
- 18 to 49 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- The study will be conducted in the central highlands of Oromia region in Ethiopia, approximately 2 hours from the capital Addis Ababa.
Key inclusion criteria (3 listed)
- Non-pregnant women 18-49 years of age
- Agree to use salt provided by the study team for the household salt disappearance study
- Provide written, informed consent.
Key exclusion criteria (4 listed)
- Currently pregnant
- Presence of acute or chronic disease (such as diarrhea, febrile illness, or underlying metabolic disorder) that might affect the participant's dietary intake or folate status
- Currently using medicines (like anticonvulsants and cancer treatments) that affect folate metabolism
- Medically prescribed restriction of salt intake
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Folate status
Time frame: one week
Red blood cell (RBC) folate concentration using a microbiological assay
Iodine status
Time frame: four weeks
24-hour urinary iodine excretion using the Sandell-Kolthoff color reaction
Discretionary salt intake
Time frame: four weeks
In-home weighed record of dietary intake
Household salt utilization
Time frame: six weeks
One-week difference in weight of salt provided by study team
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 13 Mar 2025.
- Results publication: PubMed 39673143Agbemafle I, Woldeyohannes M, Tessema M, Fereja M, Arnold CD, Banjaw BT, Hussen A, Kebebe T, Goh YE, Arabi M, Martinez H, McDonald CM, Brown KH. Assessment of Women's Discretionary Salt Intake and Household Salt Utilization in Preparation for a Salt Fortification Trial in Oromia Region, Ethiopia. Matern Child Nutr. 2025 Apr;21(2):e13768. doi: 10.1111/mcn.13768. Epub 2024 Dec 13.
- Individual participant dataSharing planned: Yes. Two years after completion of the data collection, the individual participant data (IPD) data sets will become publicly available to other investigators who have specific research questions that can be addressed by the data and that are not already under analysis by the core research team. Researchers who desire to have access to the clinical specimens will be requested to apply for the specimens and to describe the research question(s) they plan to address.
Related trials for Folate Deficiency
RecruitingPhase 3
Torvutatug Samrotecan Plus Bevacizumab as First-line Maintenance in Non-Homologous Recombination Deficiency (Non-HRD) Positive Advanced Epithelial Ovarian Cancer
Epithelial Ovarian Cancer
Active, not recruiting
Iron Absorption From IFA and MMS Supplements in Kenyan Women During the Second Trimester of Pregnancy
Pregnancy
Not yet recruitingObservational study
Non-Interventional Study of Ferretab® Comp. (Ferrous Fumarate + Folic Acid Prolonged-Release Capsules) Effects in Adult Patients With Iron Deficiency Anemia and Cardiovascular Disease
Iron Deficiency Anemia, Coronary Artery Disease
Not yet recruiting
MMS, IFA, and MMS+IFA Supplementation in Pregnant Women
Maternal Anemia, Micronutrient Deficiency
Recruiting
Folic Acid Salt Study (FISFA Zambia)
Folate Deficiency, Neural Tube Defects
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Kenneth H Brown, MD principal investigator
University of California, Davis
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Folate Deficiency and Iodine Deficiency, run by University of California, Davis at 1 site in Ethiopia.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 13 Mar 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Ethiopia. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Folate status (time frame: one week). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT05792241, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Mar 2025.